USDA licenses 75-day Cytopoint Plus for canine allergic dermatitis
The USDA has licensed Cytopoint Plus (Zoetis), a longer-acting monoclonal antibody for dogs with allergic dermatitis. It is given every 75 days, compared with every 4 to 8 weeks for the original Cytopoint. Both products target and neutralize interleukin-31, a key driver of itch. According to Zoetis, studies showed efficacy through day 75 with a safety profile similar to the original product. Cytopoint Plus is labeled for allergic dermatitis, and the original Cytopoint is also indicated for atopic dermatitis. In a Q&A with dvm360, Zoetis chief medical officer Richard Goldstein, DVM, DACVIM (SAIM), DECVIM-CA, explains how the company designed the product to last longer.
Dechra acquires stem cell developer Gallant
Dechra has acquired Gallant, an animal health biotechnology company developing regenerative therapies for dogs and cats. The deal was announced November 17 and adds programs for refractory feline chronic gingivostomatitis and osteoarthritis to Dechra's portfolio. In an email to dvm360, Dechra said Gallant will continue operating as usual for its employees, customers, and vendors. Gallant's lead feline therapy, sonruvetcel, is being developed for cats with refractory chronic gingivostomatitis and has completed 2 FDA technical sections. Dechra said the first product from Gallant's pipeline could be available as early as 2027 but has not confirmed which therapy it will be. Financial terms were not disclosed.